Plasmodium vivax malaria vaccines

Figures & data

Figure 1. A comparison of disease burden (A) and investment in research and global malaria vaccine development (B) for both, P. vivax and P. falciparum between 2007 and 2009. Figures based on references 1, 5, and 6.

Figure 2. Costs associated with research and development of various novel control measures for infectious diseases and malaria.^6,13,59

Figure 3. Timeline in the progress of vaccines tested to completion in clinical trials. (1) Vivax-1 vaccine.^28–30 (2) LSP vaccine.^31–33 (3) VMP001.^34–38 (4) PVS25H.^46–49

Figure 4. Challenges in the development of P. vivax vaccines.

Guerra CA, Howes RE, Patil AP, Gething PW, Van Boeckel TP, Temperley WH, Kabaria CW, Tatem AJ, Manh BH, Elyazar IR, et al. The international limits and population at risk of Plasmodium vivax transmission in 2009. PLoS Negl Trop Dis 2010; 4:e774; http://dx.doi.org/10.1371/journal.pntd.0000774; PMID: 20689816

 PubMed Web of Science ®Google Scholar

Gething PW, Patil AP, Smith DL, Guerra CA, Elyazar IR, Johnston GL, Tatem AJ, Hay SI. A new world malaria map: Plasmodium falciparum endemicity in 2010. Malar J 2011; 10:378; http://dx.doi.org/10.1186/1475-2875-10-378; PMID: 22185615

 PubMed Web of Science ®Google Scholar

PATH. 2011. Staying the course? Malaria Research and Development in a Time of Economic Uncerainty. Seattle. PATH. http://www.malariavaccine.org/files/RD-report-June2011.pdf, PATH, Seattle.

 Google Scholar

Douglas RG, Sadoff J, Samant V. 2008. The Vaccine Industry. Philadelphia: Saunders.

 Google Scholar

Moram M, Ropars A, Guzman J, Diaz J, Garrison C. 2005. The new landscape of neglected disease drug development. London: The Wellcome Trust.

 Google Scholar

Barr PJ, Gibson HL, Enea V, Arnot DE, Hollingdale MR, Nussenzweig V. Expression in yeast of a Plasmodium vivax antigen of potential use in a human malaria vaccine. J Exp Med 1987; 165:1160 - 71; http://dx.doi.org/10.1084/jem.165.4.1160; PMID: 3549959

 PubMed Web of Science ®Google Scholar

Herrington DA, Nardin EH, Losonsky G, Bathurst IC, Barr PJ, Hollingdale MR, Edelman R, Levine MM. Safety and immunogenicity of a recombinant sporozoite malaria vaccine against Plasmodium vivax. Am J Trop Med Hyg 1991; 45:695 - 701; PMID: 1763796

 PubMed Web of Science ®Google Scholar

Corradin G, Céspedes N, Verdini A, Kajava AV, Arévalo-Herrera M, Herrera S. Malaria vaccine development using synthetic peptides as a technical platform. Adv Immunol 2012; 114:107 - 49; http://dx.doi.org/10.1016/B978-0-12-396548-6.00005-6; PMID: 22449780

 PubMed Web of Science ®Google Scholar

Herrera S, Bonelo A, Perlaza BL, Fernández OL, Victoria L, Lenis AM, Soto L, Hurtado H, Acuña LM, Vélez JD, et al. Safety and elicitation of humoral and cellular responses in colombian malaria-naive volunteers by a Plasmodium vivax circumsporozoite protein-derived synthetic vaccine. Am J Trop Med Hyg 2005; 73:Suppl 3 - 9; PMID: 16291760

 PubMed Web of Science ®Google Scholar

Yadava A, Sattabongkot J, Washington MA, Ware LA, Majam V, Zheng H, Kumar S, Ockenhouse CF. A novel chimeric Plasmodium vivax circumsporozoite protein induces biologically functional antibodies that recognize both VK210 and VK247 sporozoites. Infect Immun 2007; 75:1177 - 85; http://dx.doi.org/10.1128/IAI.01667-06; PMID: 17158893

 PubMed Web of Science ®Google Scholar

Moon JJ, Suh H, Polhemus ME, Ockenhouse CF, Yadava A, Irvine DJ. Antigen-displaying lipid-enveloped PLGA nanoparticles as delivery agents for a Plasmodium vivax malaria vaccine. PLoS One 2012; 7:e31472; http://dx.doi.org/10.1371/journal.pone.0031472; PMID: 22328935

 PubMed Web of Science ®Google Scholar

Wu Y, Ellis RD, Shaffer D, Fontes E, Malkin EM, Mahanty S, Fay MP, Narum D, Rausch K, Miles AP, et al. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PLoS One 2008; 3:e2636; http://dx.doi.org/10.1371/journal.pone.0002636; PMID: 18612426

 PubMed Web of Science ®Google Scholar

Sattabongkot J, Tsuboi T, Hisaeda H, Tachibana M, Suwanabun N, Rungruang T, Cao YM, Stowers AW, Sirichaisinthop J, Coleman RE, et al. Blocking of transmission to mosquitoes by antibody to Plasmodium vivax malaria vaccine candidates Pvs25 and Pvs28 despite antigenic polymorphism in field isolates. Am J Trop Med Hyg 2003; 69:536 - 41; PMID: 14695092

 PubMed Web of Science ®Google Scholar